Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab

PURPOSE: Panitumumab monotherapy is approved for chemotherapy-refractory wild-type KRAS metastatic colorectal cancer (mCRC). Patient-reported outcomes—although important in the palliative setting—have not been reported in this patient population. METHODS: In a phase 3 trial (n = 463), patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Odom, Dawn, Barber, Beth, Bennett, Lee, Peeters, Marc, Zhao, Zhongyun, Kaye, James, Wolf, Michael, Wiezorek, Jeffrey
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024508/
https://www.ncbi.nlm.nih.gov/pubmed/21190026
http://dx.doi.org/10.1007/s00384-010-1112-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024508/
https://www.ncbi.nlm.nih.gov/pubmed/21190026
http://dx.doi.org/10.1007/s00384-010-1112-5

Ejemplares similares